Related Experiment Video
Updated: Dec 24, 2025
10:25
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
Published on: March 19, 2016
9.8K
Ankaferd hemostat: from molecules to medicine
Rafiye Çiftçiler1, İbrahim Celalettin Haznedaroglu1
1Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Turkish Journal of Medical Sciences
|April 15, 2020
Summary
Ankaferd hemostat (ABS) promotes a protein network for rapid hemostasis by aggregating red blood cells. This agent also shows antiproliferative effects on cancer cells, warranting further clinical investigation.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Ankaferd hemostat (ABS) is a hemostatic agent impacting red blood cell-fibrinogen interactions.
- ABS accelerates hemostasis by promoting a protein network, primarily fibrinogen gamma, linked to erythrocyte aggregation.
Purpose of the Study:
- To review the molecular basis of Ankaferd hemostat (ABS) as a hemostatic drug.
- To assess the potential pleiotropic clinical effects of ABS.
Main Methods:
- Literature search conducted in PubMed, Web of Science, and Scopus.
- Focus on molecular basis, in vivo research, case series, and controlled randomized clinical studies of ABS.
Main Results:
- ABS induces erythrocyte aggregation via spectrin, ankyrin, and actin, forming a protein network for hemostasis.
- ABS affects cell metabolism, cell cycle, and exhibits antiproliferative effects on cancer cells.
Conclusions:
- ABS functions as a hemostatic agent by accelerating wound healing through erythrocyte aggregation.
- Further controlled trials are necessary to confirm ABS's antineoplastic, anti-inflammatory, anti-infective, antifungal, and antioxidative effects.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
01:05Introduction to Hemostasis
12.6K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
12.6K
01:16Clot Retraction and Fibrinolysis
8.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
11.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.4K
01:09Coagulation
9.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.4K
01:25Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
133
Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
133